Alphamab Oncology
HKEX:9966
Alphamab Oncology
HKEX:9966
Price:
9.2
HKD
3.02%
Market Closed
Market Cap:
HK$8.9B
Relative Value
The Relative Value of one
Alphamab Oncology
stock under the Base Case scenario is
hidden
HKD.
Compared to the current market price of 9.2 HKD,
Alphamab Oncology
is
hidden
.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Alphamab Oncology Relative Value
HIDDEN
Multiples Across Competitors
Competitors Multiples
Alphamab Oncology Competitors
Alphamab Oncology Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
|
Alphamab Oncology
HKEX:9966
|
8.8B HKD | 10 | 33.7 | 23.5 | 31.9 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 643 258.8 | -159 901.4 | -194 171.3 | -191 955.6 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
405B USD | 6.8 | 172 | 16.6 | 23.6 | |
| US |
|
Astria Therapeutics Inc
NASDAQ:ATXS
|
326.4B USD | 462 374.5 | -2 631.9 | -2 377 | -2 377 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
204.8B USD | 5.6 | 26.6 | 15.2 | 15.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
186B USD | 6.3 | 21.8 | 14.8 | 14.8 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
123.3B USD | 10.3 | 31.2 | 23.9 | 24.9 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 094 | -534.3 | -581.8 | -566.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
83B USD | 5.8 | 18.4 | 14 | 16 | |
| NL |
|
argenx SE
XBRU:ARGX
|
43B EUR | 14.2 | 33.5 | 57.5 | 59 | |
| AU |
|
CSL Ltd
ASX:CSL
|
71.4B AUD | 3.2 | 16.5 | 11.4 | 14.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
